Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells
Authors
Keywords
-
Journal
JOURNAL OF CELLULAR BIOCHEMISTRY
Volume 116, Issue 12, Pages 2824-2839
Publisher
Wiley
Online
2015-05-18
DOI
10.1002/jcb.25229
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide
- (2014) Lucio Tentori et al. BMC CANCER
- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- HER2 aberrations in cancer: Implications for therapy
- (2014) Min Yan et al. CANCER TREATMENT REVIEWS
- Estrogen Receptor Mutations in Breast Cancer--New Focus on an Old Target
- (2014) C. V. Segal et al. CLINICAL CANCER RESEARCH
- The Mre11/Rad50/Nbs1 complex: Recent insights into catalytic activities and ATP-driven conformational changes
- (2014) Tanya T. Paull et al. EXPERIMENTAL CELL RESEARCH
- Familial pancreatic cancer: genetic advances
- (2014) A. K. Rustgi GENES & DEVELOPMENT
- PARP Inhibitors as P-glyoprotein Substrates
- (2014) Denise Lawlor et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Modifiers of Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: A Systematic Review and Meta-Analysis
- (2014) Tara M. Friebel et al. JNCI-Journal of the National Cancer Institute
- Breast cancer statistics, 2013
- (2013) Carol DeSantis et al. CA-A CANCER JOURNAL FOR CLINICIANS
- New approach to cancer therapy based on a molecularly defined cancer classification
- (2013) Javier Cortés et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines
- (2013) Aisling Pierce et al. CANCER BIOLOGY & THERAPY
- Optimal Targeting of HER2–PI3K Signaling in Breast Cancer: Mechanistic Insights and Clinical Implications
- (2013) Brent N. Rexer et al. CANCER RESEARCH
- Mechanisms of resistance to therapies targeting BRCA-mutant cancers
- (2013) Christopher J Lord et al. NATURE MEDICINE
- A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer
- (2013) S Postel-Vinay et al. ONCOGENE
- DNA Repair Gene Patterns as Prognostic and Predictive Factors in Molecular Breast Cancer Subtypes
- (2013) L. Santarpia et al. ONCOLOGIST
- The Genomic Landscape of Breast Cancer as a Therapeutic Roadmap
- (2013) Matthew J. Ellis et al. Cancer Discovery
- PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells
- (2012) Józefa Węsierska-Gądek et al. BIOCHEMICAL PHARMACOLOGY
- Clinicopathological Features of Homologous Recombination-Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival
- (2012) A. Mukhopadhyay et al. CANCER RESEARCH
- PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells
- (2012) H. Cheng et al. CARCINOGENESIS
- Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro
- (2012) A. G. Patel et al. CLINICAL CANCER RESEARCH
- The role of BRCA1 in DNA double-strand repair: Past and present
- (2012) Kevin W. Caestecker et al. EXPERIMENTAL CELL RESEARCH
- Targeted therapy for triple-negative breast cancer: Where are we?
- (2012) Michael J. Duffy et al. INTERNATIONAL JOURNAL OF CANCER
- Global estimates of cancer prevalence for 27 sites in the adult population in 2008
- (2012) Freddie Bray et al. INTERNATIONAL JOURNAL OF CANCER
- Proteome signatures of inflammatory activated primary human peripheral blood mononuclear cells
- (2012) Verena J. Haudek-Prinz et al. Journal of Proteomics
- Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
- (2012) Janneke E. Jaspers et al. Cancer Discovery
- Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor
- (2011) X. Liu et al. CLINICAL CANCER RESEARCH
- Therapeutic intervention by the simultaneous inhibition of DNA repair and type I or type II DNA topoisomerases: one strategy, many outcomes
- (2011) Józefa Węsierska-Gądek et al. Future Medicinal Chemistry
- Damage-specific DNA binding protein 1 (DDB1): a protein with a wide range of functions
- (2011) Barbara Iovine et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Breast cancer — one term, many entities?
- (2011) Nicholas R. Bertos et al. JOURNAL OF CLINICAL INVESTIGATION
- Decreased expression of BRCA1 in SK-BR-3 cells is the result of aberrant activation of the GABP Beta promoter by an NRF-1-containing complex
- (2011) Crista Thompson et al. Molecular Cancer
- The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
- (2011) Thomas Helleday Molecular Oncology
- Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
- (2011) Joyce O'Shaughnessy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Less label, more free: Approaches in label-free quantitative mass spectrometry
- (2011) Karlie A. Neilson et al. PROTEOMICS
- Improved LC−MS/MS Spectral Counting Statistics by Recovering Low-Scoring Spectra Matched to Confidently Identified Peptide Sequences
- (2010) Jian-Ying Zhou et al. JOURNAL OF PROTEOME RESEARCH
- Relative, label-free protein quantitation: Spectral counting error statistics from nine replicate MudPIT samples
- (2010) Bret Cooper et al. JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY
- Making the best of PARP inhibitors in ovarian cancer
- (2010) Susana Banerjee et al. Nature Reviews Clinical Oncology
- BRCA mutations in the management of breast cancer: the state of the art
- (2010) Steven A. Narod Nature Reviews Clinical Oncology
- Colorectal Cancer Due to Deficiency in DNA Mismatch Repair Function
- (2009) Andrew M. Bellizzi et al. ADVANCES IN ANATOMIC PATHOLOGY
- Preventing Carryover of Peptides and Proteins in Nano LC-MS Separations
- (2009) Goran Mitulović et al. ANALYTICAL CHEMISTRY
- Targeting the Molecular Defect in BRCA-Deficient Tumors for Cancer Therapy
- (2009) Ashok R. Venkitaraman CANCER CELL
- PARP inhibitors in cancer therapy: Two modes of attack on the cancer cell widening the clinical applications
- (2009) Yvette Drew et al. DRUG RESISTANCE UPDATES
- Outcome of treatment of human HeLa cervical cancer cells with roscovitine strongly depends on the dosage and cell cycle status prior to the treatment
- (2009) Józefa Węsierska-Gądek et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- BRCA1 and its toolbox for the maintenance of genome integrity
- (2009) Michael S.Y. Huen et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Role of MSH6 and PMS2 in the DNA Mismatch Repair Process and Carcinogenesis
- (2009) Mark A. Jenkins Surgical Oncology Clinics of North America
- 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1
- (2008) Keith A. Menear et al. JOURNAL OF MEDICINAL CHEMISTRY
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
- (2008) S. Rottenberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More